NasdaqCM:STLNHealthcare
Starling Oncology (STLN) Stock Rerates On Cash Gains As Margin Risks Linger
Starling Oncology jumped 28% to US$6.41 after its Q2 release, a sharp repricing for a stock that had already logged strong double digit gains over the past quarter. The headline is not earnings per share; the swing factor is cash and profitability.
Starling Oncology booked its second profitable quarter on an adjusted EBITDA basis and reported positive free cash flow alongside US$41.1m of cash and a fresh term loan that pushed major debt maturities out to 2031. The market moved on the day. The...